Neurohormonal blockade in chronic heart failure: How much is enough? Can there be too much?

Journal of the American College of Cardiology

Volumn 39, Issue 1, 2002, Pages 79-82

  Massie, Barry M ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BISOPROLOL; BOSENTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CARVEDILOL; CATECHOLAMINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENRASENTAN; ETANERCEPT; LISINOPRIL; METOPROLOL; NEUROHORMONE; RENIN; SPIRONOLACTONE; VALSARTAN;

CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL REGULATION; HOSPITALIZATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENALAPRIL; EPINEPHRINE; HEART FAILURE, CONGESTIVE; HUMANS; NOREPINEPHRINE; TREATMENT OUTCOME;

EID: 0037005833     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01715-6     Document Type: Editorial

References (32)

1. Neurohormonal interactions and adaptations in congestive heart failure
2. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure
3. Evaluating quality of care for patients with heart failure
4. Determinants of angiotensin II generation during converting enzyme inhibition
5. Angiotensin-II-forming pathways in normal and failing human hearts
6. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
7. Pathological hypertrophy and the cardiac interstitium: Fibrosis the renin-angiotensin-aldosterone system
8. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II
9. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction
10. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure
11. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
12. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
15. Effect of carvedilol on survival in severe chronic heart failure
16. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial
17. Concensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure
18. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
19. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
20. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin-converting enzyme inhibitor therapy in patients with heart failure
21. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
22. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study
23. Clinical trials update: Highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
24. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
25. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design
26. Update of REACH-1 and MERIT-HF clinical trials in heart failure
27. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, ENCOR, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001
28. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure
29. Heart failure 99 - The MOXCON story
30. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
31. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
32. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)